{ "disease": "myelodysplastic-syndromes", "label": "Myelodysplastic syndromes", "url": "https://usebiotransfer.org/disease/myelodysplastic-syndromes/", "built": "2026-09-12", "facts_hash": { "answers": "c2127f2d4aba", "targets": "a6f899d587f4" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-12", "trials": "2026-09-12" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "SF3B1", "ensembl": "ENSG00000115524", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "TET2", "ensembl": "ENSG00000168769", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "ASXL1", "ensembl": "ENSG00000171456", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" } ] }, { "symbol": "DNMT3A", "ensembl": "ENSG00000119772", "n_drug_entries": 2, "n_distinct_drugs": 2, "drugs": { "AZACITIDINE": "APPROVAL", "DECITABINE": "APPROVAL" }, "approved": [ "AZACITIDINE", "DECITABINE" ], "n_approved": 2, "approved_for": { "AZACITIDINE": [ "myelodysplastic syndrome", "chronic myelomonocytic leukemia", "myelodysplastic syndrome with excess blasts", "acute myeloid leukemia" ], "DECITABINE": [ "myelodysplastic syndrome with excess blasts", "myelodysplastic syndrome", "chronic myelomonocytic leukemia", "anemia", "myeloid leukemia" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "RUNX1", "ensembl": "ENSG00000159216", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "SRSF2", "ensembl": "ENSG00000161547", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "U2AF1", "ensembl": "ENSG00000160201", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "EZH2", "ensembl": "ENSG00000106462", "n_drug_entries": 3, "n_distinct_drugs": 3, "drugs": { "GSK2816126": "PHASE_1", "TAZEMETOSTAT": "APPROVAL", "TAZEMETOSTAT HYDROBROMIDE": "APPROVAL" }, "approved": [ "TAZEMETOSTAT", "TAZEMETOSTAT HYDROBROMIDE" ], "n_approved": 2, "approved_for": { "TAZEMETOSTAT": [ "follicular lymphoma" ], "TAZEMETOSTAT HYDROBROMIDE": [ "follicular lymphoma", "sarcoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "STAG2", "ensembl": "ENSG00000101972", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "IDH2", "ensembl": "ENSG00000182054", "n_drug_entries": 4, "n_distinct_drugs": 2, "drugs": { "ENASIDENIB": "APPROVAL", "VORASIDENIB": "APPROVAL" }, "approved": [ "ENASIDENIB", "VORASIDENIB" ], "n_approved": 2, "approved_for": { "ENASIDENIB": [ "acute myeloid leukemia by FAB classification", "acute myeloid leukemia" ], "VORASIDENIB": [ "astrocytoma (excluding glioblastoma)", "oligodendroglioma", "glioma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "BCL2", "ensembl": "ENSG00000171791", "n_drug_entries": 7, "n_distinct_drugs": 5, "drugs": { "APG-2575": "PHASE_3", "NAVITOCLAX": "APPROVAL", "OBATOCLAX": "PHASE_3", "OBLIMERSEN": "APPROVAL", "VENETOCLAX": "APPROVAL" }, "approved": [ "NAVITOCLAX", "OBLIMERSEN", "VENETOCLAX" ], "n_approved": 3, "approved_for": { "NAVITOCLAX": [], "OBLIMERSEN": [], "VENETOCLAX": [ "B-cell chronic lymphocytic leukemia" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] } ], "trials": { "by_antigen": { "TGF-beta ligands": { "n": 27, "n_observational": 14, "n_active": 18, "n_withdrawn": 0, "trials": [ { "nct": "NCT04064060", "title": "A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04419649", "title": "A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05181735", "title": "Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05384691", "title": "Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions", "status": "RECRUITING", "last_update": "2024-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05924100", "title": "Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD", "status": "RECRUITING", "last_update": "2024-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05925504", "title": "The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes", "status": "RECRUITING", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06670222", "title": "Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07096297", "title": "Luspatercept + Darbepoetin in MDS", "status": "RECRUITING", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01736683", "title": "Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)", "status": "COMPLETED", "last_update": "2022-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01749514", "title": "Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)", "status": "COMPLETED", "last_update": "2024-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02268383", "title": "Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)", "status": "COMPLETED", "last_update": "2024-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02631070", "title": "A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2021-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03682536", "title": "A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Na\u00efve", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03900715", "title": "An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion", "status": "COMPLETED", "last_update": "2024-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477850", "title": "A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions", "status": "COMPLETED", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04539236", "title": "Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients", "status": "SUSPENDED", "last_update": "2026-07-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05181592", "title": "Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05568225", "title": "A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)", "status": "TERMINATED", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05732961", "title": "Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05891249", "title": "A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (\u03b2-Thal) in India", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05949684", "title": "ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06006949", "title": "Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS", "status": "UNKNOWN", "last_update": "2023-08-23", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06045689", "title": "A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06113302", "title": "A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06927232", "title": "AZA+Lus VS AZA Monotherapy in HR-MDS", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07463820", "title": "A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "luspatercept", "Reblozyl", "sotatercept" ] }, "hypomethylating": { "n": 307, "n_observational": 15, "n_active": 89, "n_withdrawn": 14, "trials": [ { "nct": "NCT00801489", "title": "Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01515527", "title": "Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03113643", "title": "SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03471260", "title": "Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03661307", "title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03874052", "title": "Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140487", "title": "Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04184505", "title": "Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)", "status": "RECRUITING", "last_update": "2025-04-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04187703", "title": "5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies", "status": "RECRUITING", "last_update": "2026-05-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04243785", "title": "A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2024-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04245397", "title": "Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2025-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04275518", "title": "A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.", "status": "RECRUITING", "last_update": "2024-10-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04282187", "title": "Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04581512", "title": "Study to Evaluate the Safety and Tolerability of EP0042", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04742634", "title": "Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant", "status": "RECRUITING", "last_update": "2026-03-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04771130", "title": "A Study of BGB-11417 in Participants With Myeloid Malignancies", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04953897", "title": "Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04953910", "title": "Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04988555", "title": "A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)", "status": "RECRUITING", "last_update": "2026-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010122", "title": "ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05184842", "title": "Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML", "status": "RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05292664", "title": "Venetoclax Basket Trial for High Risk Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554406", "title": "Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05636514", "title": "Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05641259", "title": "A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05817955", "title": "Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN", "status": "RECRUITING", "last_update": "2023-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05849662", "title": "A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06046313", "title": "Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS", "status": "RECRUITING", "last_update": "2024-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06357182", "title": "Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06471946", "title": "VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS", "status": "RECRUITING", "last_update": "2024-10-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06484062", "title": "Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06502145", "title": "Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-04-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06536959", "title": "VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS", "status": "RECRUITING", "last_update": "2024-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06548230", "title": "A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-03-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06577441", "title": "Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06612944", "title": "Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification", "status": "RECRUITING", "last_update": "2024-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06641414", "title": "Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).", "status": "RECRUITING", "last_update": "2025-11-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06778187", "title": "Oral-ATO for TP53-mutated Myeloid Malignancies", "status": "RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06886425", "title": "Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies", "status": "RECRUITING", "last_update": "2025-03-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06923488", "title": "Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06928662", "title": "Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06972641", "title": "Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation", "status": "RECRUITING", "last_update": "2025-05-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07006025", "title": "A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)", "status": "RECRUITING", "last_update": "2026-01-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07044544", "title": "Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies", "status": "RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07047183", "title": "Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes", "status": "RECRUITING", "last_update": "2025-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07071155", "title": "Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07238686", "title": "Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07283094", "title": "FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07500753", "title": "A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07761533", "title": "PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002832", "title": "Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2012-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002980", "title": "Decitabine in Treating Patients With Melanoma or Other Advanced Cancer", "status": "COMPLETED", "last_update": "2013-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003361", "title": "Decitabine in Treating Patients With Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004871", "title": "Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2010-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00043134", "title": "Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2010-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00043381", "title": "Decitabine Versus Supportive Care in Adults With Advanced-stage MDS", "status": "COMPLETED", "last_update": "2024-08-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049582", "title": "Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00067808", "title": "Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2012-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00071799", "title": "A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care", "status": "COMPLETED", "last_update": "2019-10-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00075010", "title": "Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2018-11-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101179", "title": "MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-10-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00102687", "title": "Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2019-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00113321", "title": "Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure", "status": "TERMINATED", "last_update": "2012-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00114257", "title": "Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00260065", "title": "A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2013-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00282399", "title": "A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2015-10-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00321711", "title": "Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents", "status": "COMPLETED", "last_update": "2018-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00324220", "title": "A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2015-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00326170", "title": "Phase II 5-Azacytidine Plus VPA Plus ATRA", "status": "COMPLETED", "last_update": "2012-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00350818", "title": "Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)", "status": "COMPLETED", "last_update": "2012-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00357708", "title": "Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases", "status": "COMPLETED", "last_update": "2013-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00382200", "title": "Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2024-05-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00382590", "title": "Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients", "status": "COMPLETED", "last_update": "2012-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00392353", "title": "Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00414310", "title": "Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)", "status": "COMPLETED", "last_update": "2019-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00416598", "title": "Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00479232", "title": "Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)", "status": "COMPLETED", "last_update": "2015-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00495547", "title": "SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2014-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00528983", "title": "Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2019-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00619099", "title": "A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2013-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00621023", "title": "Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00660400", "title": "Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant", "status": "COMPLETED", "last_update": "2014-09-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00666497", "title": "Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2015-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00671697", "title": "Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00691938", "title": "LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2016-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00700011", "title": "Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)", "status": "TERMINATED", "last_update": "2013-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00740181", "title": "Decitabine, Cytarabine, GCSF for Refractory AML/MDS", "status": "TERMINATED", "last_update": "2022-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00744757", "title": "An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2013-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00760084", "title": "Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2011-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00778375", "title": "Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2016-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00796003", "title": "A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00828802", "title": "Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2013-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00882102", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)", "status": "COMPLETED", "last_update": "2013-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00887068", "title": "Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)", "status": "COMPLETED", "last_update": "2020-01-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00903760", "title": "Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2018-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00906334", "title": "Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk", "status": "COMPLETED", "last_update": "2017-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00915785", "title": "Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities", "status": "COMPLETED", "last_update": "2013-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00923234", "title": "Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes", "status": "TERMINATED", "last_update": "2013-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00941109", "title": "Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2023-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968071", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00986804", "title": "Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant", "status": "COMPLETED", "last_update": "2016-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01011283", "title": "To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.", "status": "TERMINATED", "last_update": "2014-10-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01048034", "title": "Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)", "status": "COMPLETED", "last_update": "2013-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01065129", "title": "Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2017-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01088373", "title": "Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q", "status": "COMPLETED", "last_update": "2017-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130506", "title": "Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2017-08-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01133886", "title": "Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure", "status": "UNKNOWN", "last_update": "2010-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01152346", "title": "Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients", "status": "COMPLETED", "last_update": "2015-01-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01165996", "title": "Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2019-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01168219", "title": "Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01186939", "title": "An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2019-11-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01211457", "title": "Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)", "status": "UNKNOWN", "last_update": "2019-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01241500", "title": "Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts", "status": "COMPLETED", "last_update": "2020-06-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01251627", "title": "Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia", "status": "COMPLETED", "last_update": "2018-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01277484", "title": "Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML", "status": "UNKNOWN", "last_update": "2015-11-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01324960", "title": "Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes", "status": "WITHDRAWN", "last_update": "2014-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01333449", "title": "Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients", "status": "TERMINATED", "last_update": "2014-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01338337", "title": "Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia", "status": "COMPLETED", "last_update": "2016-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01378416", "title": "Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2011-07-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01390311", "title": "Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant", "status": "COMPLETED", "last_update": "2015-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01404741", "title": "5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2023-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01417767", "title": "Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS", "status": "UNKNOWN", "last_update": "2016-09-09", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01420926", "title": "Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2023-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01455506", "title": "PRO#0118: Decitabine Plus Mini Flu-Bu", "status": "COMPLETED", "last_update": "2014-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01462578", "title": "Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)", "status": "COMPLETED", "last_update": "2021-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01481220", "title": "Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2013-05-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01519011", "title": "Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine", "status": "COMPLETED", "last_update": "2019-11-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522976", "title": "Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01535456", "title": "FLT-PET Imaging for MDS", "status": "TERMINATED", "last_update": "2019-12-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01546038", "title": "A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2020-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01566695", "title": "The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2025-01-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01567059", "title": "Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2017-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01593670", "title": "Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2019-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01599325", "title": "Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2019-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01607645", "title": "Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS", "status": "TERMINATED", "last_update": "2017-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01613976", "title": "A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01617226", "title": "Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS", "status": "COMPLETED", "last_update": "2021-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01674985", "title": "Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2016-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01687400", "title": "Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2018-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01690507", "title": "Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML\uff09", "status": "COMPLETED", "last_update": "2016-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01707004", "title": "Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01720225", "title": "Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk", "status": "COMPLETED", "last_update": "2020-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01729845", "title": "Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2019-02-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01747499", "title": "Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation", "status": "TERMINATED", "last_update": "2019-10-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01751867", "title": "An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2016-04-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01806116", "title": "Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation", "status": "UNKNOWN", "last_update": "2013-03-12", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01809392", "title": "Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2013-03-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01812252", "title": "Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant", "status": "COMPLETED", "last_update": "2024-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01834248", "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01835587", "title": "Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).", "status": "COMPLETED", "last_update": "2018-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01846624", "title": "Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2018-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01869114", "title": "Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy", "status": "COMPLETED", "last_update": "2025-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01873703", "title": "Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2018-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01893320", "title": "Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2022-02-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01893372", "title": "Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2020-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01908387", "title": "Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms", "status": "TERMINATED", "last_update": "2015-07-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01928537", "title": "Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine", "status": "COMPLETED", "last_update": "2020-06-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01993641", "title": "Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA", "status": "COMPLETED", "last_update": "2017-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02010645", "title": "Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2020-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02013102", "title": "A Phase \u2163 Study of Decitabine in Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2013-12-17", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02017457", "title": "Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.", "status": "COMPLETED", "last_update": "2019-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02029417", "title": "Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2016-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02038777", "title": "A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies", "status": "COMPLETED", "last_update": "2025-02-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02084563", "title": "Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms", "status": "COMPLETED", "last_update": "2016-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02085408", "title": "Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-12-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02103478", "title": "Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2024-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02117219", "title": "Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2019-05-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02121418", "title": "Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm", "status": "COMPLETED", "last_update": "2018-04-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02129101", "title": "Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies", "status": "COMPLETED", "last_update": "2019-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02141477", "title": "Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2018-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02147873", "title": "Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL", "status": "TERMINATED", "last_update": "2016-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02159040", "title": "Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.", "status": "TERMINATED", "last_update": "2017-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02190695", "title": "Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS", "status": "COMPLETED", "last_update": "2021-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02197676", "title": "A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response", "status": "COMPLETED", "last_update": "2018-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02223052", "title": "Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies", "status": "COMPLETED", "last_update": "2020-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02228525", "title": "Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2022-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264873", "title": "Phase I, Dose Escalation Study of Decitabine", "status": "COMPLETED", "last_update": "2018-10-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02269280", "title": "Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02272478", "title": "Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations", "status": "UNKNOWN", "last_update": "2020-01-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02281084", "title": "Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2024-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02319369", "title": "Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2021-10-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02458235", "title": "Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2020-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02469415", "title": "Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)", "status": "TERMINATED", "last_update": "2018-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02488408", "title": "A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS", "status": "COMPLETED", "last_update": "2024-12-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02497404", "title": "Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR", "status": "COMPLETED", "last_update": "2021-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530463", "title": "Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02562443", "title": "Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA", "status": "TERMINATED", "last_update": "2022-09-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02564536", "title": "Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)", "status": "WITHDRAWN", "last_update": "2017-05-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02587598", "title": "Study of INCB053914 in Subjects With Advanced Malignancies", "status": "TERMINATED", "last_update": "2021-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02599649", "title": "Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)", "status": "TERMINATED", "last_update": "2020-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02610777", "title": "An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)", "status": "COMPLETED", "last_update": "2022-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02649790", "title": "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications", "status": "COMPLETED", "last_update": "2025-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02719574", "title": "Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation", "status": "COMPLETED", "last_update": "2026-06-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02721875", "title": "Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes", "status": "TERMINATED", "last_update": "2018-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02744742", "title": "G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT", "status": "COMPLETED", "last_update": "2022-02-14", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02779569", "title": "A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)", "status": "UNKNOWN", "last_update": "2017-11-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02782468", "title": "A Study of Pevonedistat in Adult East Asian Participants", "status": "COMPLETED", "last_update": "2023-11-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02807558", "title": "A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2024-12-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02890329", "title": "Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02921061", "title": "Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS", "status": "COMPLETED", "last_update": "2020-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02942290", "title": "A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Na\u00efve Higher-Risk Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02944955", "title": "A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02953561", "title": "Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2020-10-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02981615", "title": "Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients", "status": "COMPLETED", "last_update": "2023-11-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03030612", "title": "A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2023-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03045510", "title": "Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent", "status": "UNKNOWN", "last_update": "2017-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03066648", "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS", "status": "COMPLETED", "last_update": "2025-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03072043", "title": "Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms", "status": "COMPLETED", "last_update": "2022-01-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03092674", "title": "Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2025-01-16", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03094637", "title": "Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2023-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03113071", "title": "Safety and Activity of Digoxin With Decitabine in Adult AML and MDS", "status": "TERMINATED", "last_update": "2021-03-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03146871", "title": "Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent", "status": "TERMINATED", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03164057", "title": "A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03184935", "title": "Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife\u00ae-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)", "status": "SUSPENDED", "last_update": "2026-04-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03217903", "title": "High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)", "status": "UNKNOWN", "last_update": "2019-08-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03306264", "title": "Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML", "status": "COMPLETED", "last_update": "2024-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03356080", "title": "DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess", "status": "UNKNOWN", "last_update": "2017-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03358719", "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03377725", "title": "Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)", "status": "WITHDRAWN", "last_update": "2023-08-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03397173", "title": "TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid", "status": "COMPLETED", "last_update": "2021-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03404193", "title": "Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03486353", "title": "A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome", "status": "WITHDRAWN", "last_update": "2024-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03502668", "title": "Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS", "status": "COMPLETED", "last_update": "2026-04-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03564873", "title": "Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03593915", "title": "A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS", "status": "TERMINATED", "last_update": "2023-11-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03594149", "title": "Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients", "status": "COMPLETED", "last_update": "2026-01-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03613532", "title": "Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03813147", "title": "Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2025-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03813186", "title": "Effect of Food on Blood Levels of ASTX727", "status": "COMPLETED", "last_update": "2024-08-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03843528", "title": "Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03862157", "title": "Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03873311", "title": "Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy", "status": "UNKNOWN", "last_update": "2022-03-15", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03906695", "title": "Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946670", "title": "A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).", "status": "TERMINATED", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03969446", "title": "Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory", "status": "SUSPENDED", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03978364", "title": "A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC", "status": "UNKNOWN", "last_update": "2019-06-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04013880", "title": "ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2020-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04022785", "title": "PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2022-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04055844", "title": "Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS", "status": "COMPLETED", "last_update": "2023-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04093570", "title": "A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04097470", "title": "Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04128020", "title": "Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia", "status": "WITHDRAWN", "last_update": "2020-10-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04139434", "title": "Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML", "status": "COMPLETED", "last_update": "2026-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04146038", "title": "Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease", "status": "COMPLETED", "last_update": "2023-05-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04155580", "title": "A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2024-08-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04160052", "title": "Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2026-02-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04173533", "title": "Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT", "status": "COMPLETED", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04202003", "title": "A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2024-04-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04216355", "title": "Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT", "status": "UNKNOWN", "last_update": "2020-01-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04241549", "title": "A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment", "status": "COMPLETED", "last_update": "2023-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04358393", "title": "A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS", "status": "UNKNOWN", "last_update": "2024-02-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04401748", "title": "Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04487106", "title": "Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2025-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04609826", "title": "A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2025-10-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04623944", "title": "NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04638309", "title": "APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04655755", "title": "Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04713956", "title": "G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT", "status": "UNKNOWN", "last_update": "2021-01-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04730258", "title": "A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04734990", "title": "Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04752163", "title": "DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia", "status": "TERMINATED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04809181", "title": "Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04878432", "title": "STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS", "status": "TERMINATED", "last_update": "2025-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04891757", "title": "FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04937166", "title": "A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies", "status": "TERMINATED", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04964518", "title": "A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)", "status": "UNKNOWN", "last_update": "2023-10-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04980404", "title": "Inqovi Maintenance Therapy in Myeloid Neoplasms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04985656", "title": "A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes", "status": "WITHDRAWN", "last_update": "2021-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04999943", "title": "Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2021-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05038592", "title": "Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05048498", "title": "Pharmacokinetics, Tolerability and Safety of NEX-18a", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05148234", "title": "BMS-986253 in Myelodysplastic Syndromes", "status": "TERMINATED", "last_update": "2025-09-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05201066", "title": "Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05379166", "title": "Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05426798", "title": "Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes", "status": "UNKNOWN", "last_update": "2022-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05448599", "title": "A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS", "status": "UNKNOWN", "last_update": "2023-03-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05453552", "title": "G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT", "status": "UNKNOWN", "last_update": "2023-03-21", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05455294", "title": "Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05456269", "title": "A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS", "status": "WITHDRAWN", "last_update": "2023-10-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05469737", "title": "A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554419", "title": "Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564650", "title": "Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05600894", "title": "Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05673057", "title": "Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05766514", "title": "Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction", "status": "WITHDRAWN", "last_update": "2025-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05782127", "title": "Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05796570", "title": "A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05823480", "title": "Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS", "status": "WITHDRAWN", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05823714", "title": "Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT", "status": "UNKNOWN", "last_update": "2023-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05829226", "title": "A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2026-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05835011", "title": "A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)", "status": "TERMINATED", "last_update": "2024-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05883956", "title": "A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05918055", "title": "Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes", "status": "TERMINATED", "last_update": "2025-12-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05970822", "title": "Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML", "status": "UNKNOWN", "last_update": "2023-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06091267", "title": "PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06279338", "title": "A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score", "status": "UNKNOWN", "last_update": "2024-02-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06284460", "title": "Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms", "status": "WITHDRAWN", "last_update": "2026-02-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06337331", "title": "Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant", "status": "WITHDRAWN", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06572631", "title": "Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor", "status": "WITHDRAWN", "last_update": "2025-05-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06598384", "title": "VA as Maintenance Therapy Post Allo-HSCT in MDS and AML", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06900088", "title": "Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153497", "title": "Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07387354", "title": "Pacritinib With Aza for Upfront Myelodysplastic Syndrome", "status": "WITHDRAWN", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07617363", "title": "ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07710534", "title": "Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07735117", "title": "Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 6, "n_observational": 0, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT01390311", "title": "Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant", "status": "COMPLETED", "last_update": "2015-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01593670", "title": "Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2019-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02017457", "title": "Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.", "status": "COMPLETED", "last_update": "2019-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02458235", "title": "Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2020-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04623944", "title": "NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06572631", "title": "Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor", "status": "WITHDRAWN", "last_update": "2025-05-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "azacitidine", "decitabine", "Inqovi", "Onureg" ] }, "telomerase": { "n": 4, "n_observational": 1, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT06247787", "title": "A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01731951", "title": "Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis", "status": "COMPLETED", "last_update": "2021-09-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02598661", "title": "Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05583552", "title": "Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "imetelstat", "Rytelo" ] }, "CD47": { "n": 12, "n_observational": 0, "n_active": 1, "n_withdrawn": 3, "trials": [ { "nct": "NCT02641002", "title": "A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2018-10-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02663518", "title": "A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors", "status": "TERMINATED", "last_update": "2024-05-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02678338", "title": "CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies", "status": "COMPLETED", "last_update": "2019-02-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04313881", "title": "Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2024-06-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04417517", "title": "A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)", "status": "TERMINATED", "last_update": "2025-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04900350", "title": "A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05367401", "title": "A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants", "status": "WITHDRAWN", "last_update": "2024-04-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05607199", "title": "A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics", "status": "TERMINATED", "last_update": "2026-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05823480", "title": "Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS", "status": "WITHDRAWN", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05829434", "title": "Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS", "status": "WITHDRAWN", "last_update": "2024-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05835011", "title": "A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)", "status": "TERMINATED", "last_update": "2024-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06008405", "title": "Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy", "status": "UNKNOWN", "last_update": "2023-09-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "CD47", "magrolimab" ] }, "TIM-3": { "n": 11, "n_observational": 0, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT03066648", "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS", "status": "COMPLETED", "last_update": "2025-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940352", "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2025-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946670", "title": "A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).", "status": "TERMINATED", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04266301", "title": "Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)", "status": "TERMINATED", "last_update": "2026-01-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04810611", "title": "Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS", "status": "TERMINATED", "last_update": "2025-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04812548", "title": "A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants", "status": "TERMINATED", "last_update": "2025-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04823624", "title": "MBG453 in Lower Risk MDS", "status": "TERMINATED", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04878432", "title": "STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS", "status": "TERMINATED", "last_update": "2025-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05201066", "title": "Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05367401", "title": "A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants", "status": "WITHDRAWN", "last_update": "2024-04-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05426798", "title": "Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes", "status": "UNKNOWN", "last_update": "2022-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "TIM-3", "sabatolimab" ] }, "BCL-2": { "n": 116, "n_observational": 2, "n_active": 74, "n_withdrawn": 4, "trials": [ { "nct": "NCT02115295", "title": "Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03113643", "title": "SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03214562", "title": "Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03471260", "title": "Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03661307", "title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03850574", "title": "Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03874052", "title": "Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04068597", "title": "Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140487", "title": "Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04256317", "title": "A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04581512", "title": "Study to Evaluate the Safety and Tolerability of EP0042", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04628026", "title": "Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04708054", "title": "Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04771130", "title": "A Study of BGB-11417 in Participants With Myeloid Malignancies", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04988555", "title": "A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)", "status": "RECRUITING", "last_update": "2026-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010122", "title": "ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05025098", "title": "Precision Therapy Versus Standard Therapy in AML and MDS in Elderly", "status": "RECRUITING", "last_update": "2021-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05184842", "title": "Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML", "status": "RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05211570", "title": "AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05292664", "title": "Venetoclax Basket Trial for High Risk Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05342584", "title": "Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS", "status": "RECRUITING", "last_update": "2026-01-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05365035", "title": "A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts", "status": "RECRUITING", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554406", "title": "Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05584761", "title": "Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML", "status": "RECRUITING", "last_update": "2022-10-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05641259", "title": "A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05807932", "title": "Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML", "status": "RECRUITING", "last_update": "2024-05-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05986240", "title": "Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML", "status": "RECRUITING", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06046313", "title": "Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS", "status": "RECRUITING", "last_update": "2024-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06329999", "title": "A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML", "status": "RECRUITING", "last_update": "2024-03-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06357182", "title": "Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06372717", "title": "A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06399640", "title": "Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06419634", "title": "Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06471946", "title": "VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS", "status": "RECRUITING", "last_update": "2024-10-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06501196", "title": "A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06536959", "title": "VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS", "status": "RECRUITING", "last_update": "2024-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06548230", "title": "A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-03-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06612944", "title": "Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification", "status": "RECRUITING", "last_update": "2024-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06778187", "title": "Oral-ATO for TP53-mutated Myeloid Malignancies", "status": "RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06918834", "title": "Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients", "status": "RECRUITING", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06972641", "title": "Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation", "status": "RECRUITING", "last_update": "2025-05-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07044544", "title": "Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies", "status": "RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07047183", "title": "Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes", "status": "RECRUITING", "last_update": "2025-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07183878", "title": "Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07228273", "title": "Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07238686", "title": "Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07270978", "title": "Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07283094", "title": "FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01211457", "title": "Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)", "status": "UNKNOWN", "last_update": "2019-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02250937", "title": "Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02392572", "title": "ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02397720", "title": "Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02920541", "title": "Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2019-05-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02942290", "title": "A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Na\u00efve Higher-Risk Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02966782", "title": "A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2023-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03059615", "title": "A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS", "status": "WITHDRAWN", "last_update": "2020-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03176277", "title": "A Study of ONO-7475 in Patients With Acute Leukemias", "status": "TERMINATED", "last_update": "2024-07-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03404193", "title": "Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03613532", "title": "Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03862157", "title": "Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940352", "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2025-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03969446", "title": "Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory", "status": "SUSPENDED", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04017546", "title": "CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04146038", "title": "Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease", "status": "COMPLETED", "last_update": "2023-05-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04160052", "title": "Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2026-02-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04227847", "title": "A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278768", "title": "Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "status": "SUSPENDED", "last_update": "2026-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04284787", "title": "BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04401748", "title": "Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "status": "TERMINATED", "last_update": "2025-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04487106", "title": "Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2025-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04550442", "title": "Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia", "status": "TERMINATED", "last_update": "2026-06-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04609826", "title": "A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2025-10-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04655755", "title": "Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04752163", "title": "DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia", "status": "TERMINATED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04809181", "title": "Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04812548", "title": "A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants", "status": "TERMINATED", "last_update": "2025-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04874194", "title": "Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1", "status": "TERMINATED", "last_update": "2025-11-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04912063", "title": "Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2024-02-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04937166", "title": "A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies", "status": "TERMINATED", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05005299", "title": "Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation", "status": "UNKNOWN", "last_update": "2023-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05107856", "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies", "status": "TERMINATED", "last_update": "2024-01-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05168202", "title": "A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes", "status": "TERMINATED", "last_update": "2025-09-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05201066", "title": "Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05209152", "title": "AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia", "status": "TERMINATED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05275439", "title": "Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML", "status": "TERMINATED", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05367401", "title": "A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants", "status": "WITHDRAWN", "last_update": "2024-04-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05379166", "title": "Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05428969", "title": "A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05448599", "title": "A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS", "status": "UNKNOWN", "last_update": "2023-03-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05455294", "title": "Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554419", "title": "Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564650", "title": "Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05600894", "title": "Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05665530", "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies", "status": "COMPLETED", "last_update": "2026-01-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05673057", "title": "Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05766514", "title": "Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction", "status": "WITHDRAWN", "last_update": "2025-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05782127", "title": "Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05823714", "title": "Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT", "status": "UNKNOWN", "last_update": "2023-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05829226", "title": "A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2026-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06050941", "title": "Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06109064", "title": "Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS", "status": "UNKNOWN", "last_update": "2023-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06337331", "title": "Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant", "status": "WITHDRAWN", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06454409", "title": "Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "SUSPENDED", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563804", "title": "A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML", "status": "TERMINATED", "last_update": "2026-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06598384", "title": "VA as Maintenance Therapy Post Allo-HSCT in MDS and AML", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06765928", "title": "Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153497", "title": "Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07214064", "title": "Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation", "status": "NOT_YET_RECRUITING", "last_update": "2025-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07319793", "title": "Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07616089", "title": "Phase I Study of FXS0683 in the Treatment of Blood Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07710534", "title": "Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07735117", "title": "Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "BCL-2", "venetoclax" ] }, "IDH2": { "n": 14, "n_observational": 1, "n_active": 9, "n_withdrawn": 0, "trials": [ { "nct": "NCT03383575", "title": "Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03683433", "title": "Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06550713", "title": "A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies", "status": "RECRUITING", "last_update": "2024-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06577441", "title": "Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01915498", "title": "Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation", "status": "COMPLETED", "last_update": "2024-10-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02492737", "title": "Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation", "status": "COMPLETED", "last_update": "2019-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02632708", "title": "Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03744390", "title": "IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03839771", "title": "A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04522895", "title": "IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05282459", "title": "Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation", "status": "COMPLETED", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "IDH2", "enasidenib" ] }, "IDH1": { "n": 24, "n_observational": 1, "n_active": 16, "n_withdrawn": 3, "trials": [ { "nct": "NCT02074839", "title": "Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03471260", "title": "Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04493164", "title": "CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06465953", "title": "Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06543381", "title": "Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06566742", "title": "A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06918834", "title": "Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients", "status": "RECRUITING", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07607418", "title": "Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02381886", "title": "A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02492737", "title": "Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation", "status": "COMPLETED", "last_update": "2019-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02632708", "title": "Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02719574", "title": "Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation", "status": "COMPLETED", "last_update": "2026-06-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03173248", "title": "Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03503409", "title": "IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03839771", "title": "A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04013880", "title": "ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2020-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044209", "title": "A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS", "status": "WITHDRAWN", "last_update": "2022-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04250051", "title": "Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2026-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "status": "TERMINATED", "last_update": "2025-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06218771", "title": "A Study of TQB3454 Tablets in Patients With Blood Tumors", "status": "UNKNOWN", "last_update": "2024-01-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06597734", "title": "A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm", "status": "WITHDRAWN", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153497", "title": "Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "IDH1", "ivosidenib" ] }, "erythropoietin": { "n": 50, "n_observational": 7, "n_active": 11, "n_withdrawn": 2, "trials": [ { "nct": "NCT05181735", "title": "Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07096297", "title": "Luspatercept + Darbepoetin in MDS", "status": "RECRUITING", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07422480", "title": "A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003138", "title": "Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2023-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003681", "title": "Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2009-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00053001", "title": "Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00071799", "title": "A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care", "status": "COMPLETED", "last_update": "2019-10-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00095264", "title": "A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2010-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00230321", "title": "A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2013-02-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00234143", "title": "Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)", "status": "UNKNOWN", "last_update": "2009-03-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00379912", "title": "Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes", "status": "TERMINATED", "last_update": "2018-02-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00398047", "title": "Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes", "status": "TERMINATED", "last_update": "2018-09-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00437450", "title": "Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid", "status": "UNKNOWN", "last_update": "2009-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00443339", "title": "Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)", "status": "UNKNOWN", "last_update": "2007-05-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00446602", "title": "A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)", "status": "WITHDRAWN", "last_update": "2016-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00495547", "title": "SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2014-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00520468", "title": "Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS", "status": "COMPLETED", "last_update": "2012-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00551291", "title": "A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.", "status": "COMPLETED", "last_update": "2016-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00656448", "title": "A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS", "status": "COMPLETED", "last_update": "2018-05-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00695396", "title": "A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion", "status": "TERMINATED", "last_update": "2012-10-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00804050", "title": "Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts", "status": "TERMINATED", "last_update": "2011-06-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00843882", "title": "Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00910858", "title": "A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2013-09-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01015352", "title": "Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)", "status": "COMPLETED", "last_update": "2014-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01034657", "title": "LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)", "status": "TERMINATED", "last_update": "2017-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01039350", "title": "Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.", "status": "TERMINATED", "last_update": "2010-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01048034", "title": "Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)", "status": "COMPLETED", "last_update": "2013-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01196715", "title": "Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2025-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01222195", "title": "Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2012-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01338337", "title": "Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia", "status": "COMPLETED", "last_update": "2016-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01356875", "title": "Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy", "status": "UNKNOWN", "last_update": "2011-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01362140", "title": "Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2017-12-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01381809", "title": "An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2016-03-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01497145", "title": "A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2015-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01718379", "title": "Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.", "status": "COMPLETED", "last_update": "2016-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01868477", "title": "Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.", "status": "COMPLETED", "last_update": "2018-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02145026", "title": "A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2020-04-24", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02175277", "title": "Darbepoetin Alfa MDS Companion Protocol", "status": "COMPLETED", "last_update": "2018-11-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02428686", "title": "Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2015-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02431351", "title": "Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients", "status": "WITHDRAWN", "last_update": "2023-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02807558", "title": "A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2024-12-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03223961", "title": "A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03263091", "title": "Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden", "status": "TERMINATED", "last_update": "2024-08-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03598582", "title": "Biological Predictive Factors of Response to ESA in Low Risk MDS Patients", "status": "COMPLETED", "last_update": "2018-07-26", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03682536", "title": "A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Na\u00efve", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04798339", "title": "Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05891249", "title": "A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (\u03b2-Thal) in India", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05949684", "title": "ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07463820", "title": "A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "erythropoietin", "epoetin", "darbepoetin" ] } }, "by_drug": { "APG-2575": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06641414", "title": "Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).", "status": "RECRUITING", "last_update": "2025-11-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04964518", "title": "A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)", "status": "UNKNOWN", "last_update": "2023-10-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AZACITIDINE": { "n": 191, "n_observational": 9, "n_active": 50, "n_withdrawn": 7, "trials": [ { "nct": "NCT03113643", "title": "SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03661307", "title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03874052", "title": "Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140487", "title": "Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04184505", "title": "Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)", "status": "RECRUITING", "last_update": "2025-04-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04243785", "title": "A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2024-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04245397", "title": "Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2025-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04275518", "title": "A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.", "status": "RECRUITING", "last_update": "2024-10-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04581512", "title": "Study to Evaluate the Safety and Tolerability of EP0042", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04771130", "title": "A Study of BGB-11417 in Participants With Myeloid Malignancies", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04988555", "title": "A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)", "status": "RECRUITING", "last_update": "2026-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05292664", "title": "Venetoclax Basket Trial for High Risk Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554406", "title": "Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05636514", "title": "Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05641259", "title": "A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05817955", "title": "Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN", "status": "RECRUITING", "last_update": "2023-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05849662", "title": "A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06046313", "title": "Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS", "status": "RECRUITING", "last_update": "2024-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06357182", "title": "Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06471946", "title": "VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS", "status": "RECRUITING", "last_update": "2024-10-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06548230", "title": "A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-03-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06641414", "title": "Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).", "status": "RECRUITING", "last_update": "2025-11-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06778187", "title": "Oral-ATO for TP53-mutated Myeloid Malignancies", "status": "RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06886425", "title": "Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies", "status": "RECRUITING", "last_update": "2025-03-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06972641", "title": "Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation", "status": "RECRUITING", "last_update": "2025-05-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07006025", "title": "A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)", "status": "RECRUITING", "last_update": "2026-01-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07044544", "title": "Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies", "status": "RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07047183", "title": "Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes", "status": "RECRUITING", "last_update": "2025-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07071155", "title": "Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07238686", "title": "Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07761533", "title": "PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002832", "title": "Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2012-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002980", "title": "Decitabine in Treating Patients With Melanoma or Other Advanced Cancer", "status": "COMPLETED", "last_update": "2013-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004871", "title": "Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2010-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00043134", "title": "Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2010-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00043381", "title": "Decitabine Versus Supportive Care in Adults With Advanced-stage MDS", "status": "COMPLETED", "last_update": "2024-08-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049582", "title": "Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00071799", "title": "A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care", "status": "COMPLETED", "last_update": "2019-10-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101179", "title": "MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-10-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00102687", "title": "Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2019-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00260065", "title": "A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2013-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00321711", "title": "Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents", "status": "COMPLETED", "last_update": "2018-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00324220", "title": "A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2015-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00326170", "title": "Phase II 5-Azacytidine Plus VPA Plus ATRA", "status": "COMPLETED", "last_update": "2012-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00350818", "title": "Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)", "status": "COMPLETED", "last_update": "2012-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00357708", "title": "Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases", "status": "COMPLETED", "last_update": "2013-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00382590", "title": "Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients", "status": "COMPLETED", "last_update": "2012-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00392353", "title": "Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00495547", "title": "SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2014-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00528983", "title": "Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2019-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00619099", "title": "A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2013-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00621023", "title": "Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00660400", "title": "Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant", "status": "COMPLETED", "last_update": "2014-09-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00666497", "title": "Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2015-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00671697", "title": "Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00691938", "title": "LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2016-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00700011", "title": "Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)", "status": "TERMINATED", "last_update": "2013-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00778375", "title": "Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2016-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00796003", "title": "A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00828802", "title": "Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2013-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00882102", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)", "status": "COMPLETED", "last_update": "2013-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00887068", "title": "Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)", "status": "COMPLETED", "last_update": "2020-01-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00915785", "title": "Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities", "status": "COMPLETED", "last_update": "2013-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00923234", "title": "Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes", "status": "TERMINATED", "last_update": "2013-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00941109", "title": "Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2023-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00986804", "title": "Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant", "status": "COMPLETED", "last_update": "2016-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01011283", "title": "To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.", "status": "TERMINATED", "last_update": "2014-10-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01048034", "title": "Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)", "status": "COMPLETED", "last_update": "2013-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01065129", "title": "Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2017-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01088373", "title": "Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q", "status": "COMPLETED", "last_update": "2017-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130506", "title": "Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2017-08-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01152346", "title": "Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients", "status": "COMPLETED", "last_update": "2015-01-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01168219", "title": "Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01186939", "title": "An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2019-11-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01324960", "title": "Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes", "status": "WITHDRAWN", "last_update": "2014-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01333449", "title": "Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients", "status": "TERMINATED", "last_update": "2014-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01338337", "title": "Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia", "status": "COMPLETED", "last_update": "2016-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01390311", "title": "Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant", "status": "COMPLETED", "last_update": "2015-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01404741", "title": "5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2023-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01417767", "title": "Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS", "status": "UNKNOWN", "last_update": "2016-09-09", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01420926", "title": "Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2023-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01462578", "title": "Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)", "status": "COMPLETED", "last_update": "2021-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01481220", "title": "Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2013-05-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01519011", "title": "Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine", "status": "COMPLETED", "last_update": "2019-11-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522976", "title": "Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01535456", "title": "FLT-PET Imaging for MDS", "status": "TERMINATED", "last_update": "2019-12-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01566695", "title": "The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2025-01-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01567059", "title": "Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2017-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01599325", "title": "Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2019-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01613976", "title": "A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01617226", "title": "Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS", "status": "COMPLETED", "last_update": "2021-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01690507", "title": "Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML\uff09", "status": "COMPLETED", "last_update": "2016-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01707004", "title": "Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01747499", "title": "Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation", "status": "TERMINATED", "last_update": "2019-10-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01809392", "title": "Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2013-03-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01812252", "title": "Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant", "status": "COMPLETED", "last_update": "2024-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01834248", "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01835587", "title": "Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).", "status": "COMPLETED", "last_update": "2018-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01846624", "title": "Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2018-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01869114", "title": "Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy", "status": "COMPLETED", "last_update": "2025-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01873703", "title": "Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2018-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01908387", "title": "Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms", "status": "TERMINATED", "last_update": "2015-07-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02017457", "title": "Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.", "status": "COMPLETED", "last_update": "2019-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02029417", "title": "Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2016-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02038777", "title": "A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies", "status": "COMPLETED", "last_update": "2025-02-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02117219", "title": "Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2019-05-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02129101", "title": "Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies", "status": "COMPLETED", "last_update": "2019-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02147873", "title": "Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL", "status": "TERMINATED", "last_update": "2016-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02159040", "title": "Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.", "status": "TERMINATED", "last_update": "2017-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02223052", "title": "Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies", "status": "COMPLETED", "last_update": "2020-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02228525", "title": "Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2022-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02272478", "title": "Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations", "status": "UNKNOWN", "last_update": "2020-01-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02281084", "title": "Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2024-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02319369", "title": "Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2021-10-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02458235", "title": "Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2020-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02488408", "title": "A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS", "status": "COMPLETED", "last_update": "2024-12-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02497404", "title": "Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR", "status": "COMPLETED", "last_update": "2021-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530463", "title": "Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02562443", "title": "Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA", "status": "TERMINATED", "last_update": "2022-09-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02587598", "title": "Study of INCB053914 in Subjects With Advanced Malignancies", "status": "TERMINATED", "last_update": "2021-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02599649", "title": "Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)", "status": "TERMINATED", "last_update": "2020-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02610777", "title": "An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)", "status": "COMPLETED", "last_update": "2022-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02719574", "title": "Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation", "status": "COMPLETED", "last_update": "2026-06-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02721875", "title": "Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes", "status": "TERMINATED", "last_update": "2018-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02779569", "title": "A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)", "status": "UNKNOWN", "last_update": "2017-11-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02782468", "title": "A Study of Pevonedistat in Adult East Asian Participants", "status": "COMPLETED", "last_update": "2023-11-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02807558", "title": "A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2024-12-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02890329", "title": "Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02921061", "title": "Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS", "status": "COMPLETED", "last_update": "2020-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02942290", "title": "A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Na\u00efve Higher-Risk Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02944955", "title": "A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02953561", "title": "Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2020-10-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02981615", "title": "Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients", "status": "COMPLETED", "last_update": "2023-11-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03030612", "title": "A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2023-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03072043", "title": "Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms", "status": "COMPLETED", "last_update": "2022-01-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03094637", "title": "Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2023-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03113071", "title": "Safety and Activity of Digoxin With Decitabine in Adult AML and MDS", "status": "TERMINATED", "last_update": "2021-03-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03164057", "title": "A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03184935", "title": "Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife\u00ae-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)", "status": "SUSPENDED", "last_update": "2026-04-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03217903", "title": "High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)", "status": "UNKNOWN", "last_update": "2019-08-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03306264", "title": "Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML", "status": "COMPLETED", "last_update": "2024-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03358719", "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03397173", "title": "TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid", "status": "COMPLETED", "last_update": "2021-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03404193", "title": "Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03486353", "title": "A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome", "status": "WITHDRAWN", "last_update": "2024-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03564873", "title": "Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03593915", "title": "A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS", "status": "TERMINATED", "last_update": "2023-11-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03594149", "title": "Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients", "status": "COMPLETED", "last_update": "2026-01-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03813147", "title": "Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2025-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03843528", "title": "Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03873311", "title": "Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy", "status": "UNKNOWN", "last_update": "2022-03-15", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03969446", "title": "Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory", "status": "SUSPENDED", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03978364", "title": "A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC", "status": "UNKNOWN", "last_update": "2019-06-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04022785", "title": "PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2022-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04128020", "title": "Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia", "status": "WITHDRAWN", "last_update": "2020-10-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04139434", "title": "Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML", "status": "COMPLETED", "last_update": "2026-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04173533", "title": "Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT", "status": "COMPLETED", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04202003", "title": "A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2024-04-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04216355", "title": "Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT", "status": "UNKNOWN", "last_update": "2020-01-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04241549", "title": "A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment", "status": "COMPLETED", "last_update": "2023-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04358393", "title": "A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS", "status": "UNKNOWN", "last_update": "2024-02-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04401748", "title": "Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04487106", "title": "Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2025-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04609826", "title": "A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2025-10-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04638309", "title": "APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04730258", "title": "A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04809181", "title": "Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04878432", "title": "STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS", "status": "TERMINATED", "last_update": "2025-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04937166", "title": "A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies", "status": "TERMINATED", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04964518", "title": "A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)", "status": "UNKNOWN", "last_update": "2023-10-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05038592", "title": "Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05048498", "title": "Pharmacokinetics, Tolerability and Safety of NEX-18a", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05148234", "title": "BMS-986253 in Myelodysplastic Syndromes", "status": "TERMINATED", "last_update": "2025-09-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05448599", "title": "A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS", "status": "UNKNOWN", "last_update": "2023-03-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05453552", "title": "G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT", "status": "UNKNOWN", "last_update": "2023-03-21", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05455294", "title": "Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05469737", "title": "A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554419", "title": "Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564650", "title": "Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05673057", "title": "Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05766514", "title": "Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction", "status": "WITHDRAWN", "last_update": "2025-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05796570", "title": "A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05823480", "title": "Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS", "status": "WITHDRAWN", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05823714", "title": "Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT", "status": "UNKNOWN", "last_update": "2023-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05970822", "title": "Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML", "status": "UNKNOWN", "last_update": "2023-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06279338", "title": "A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score", "status": "UNKNOWN", "last_update": "2024-02-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06337331", "title": "Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant", "status": "WITHDRAWN", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06598384", "title": "VA as Maintenance Therapy Post Allo-HSCT in MDS and AML", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06900088", "title": "Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07387354", "title": "Pacritinib With Aza for Upfront Myelodysplastic Syndrome", "status": "WITHDRAWN", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07735117", "title": "Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "CENERSEN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02243124", "title": "A Study of Aezea\u00ae (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2021-02-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DECITABINE": { "n": 174, "n_observational": 9, "n_active": 47, "n_withdrawn": 9, "trials": [ { "nct": "NCT00801489", "title": "Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01515527", "title": "Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03661307", "title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04187703", "title": "5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies", "status": "RECRUITING", "last_update": "2026-05-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04245397", "title": "Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2025-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04282187", "title": "Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04742634", "title": "Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant", "status": "RECRUITING", "last_update": "2026-03-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04953897", "title": "Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04953910", "title": "Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010122", "title": "ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05184842", "title": "Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML", "status": "RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05636514", "title": "Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06046313", "title": "Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS", "status": "RECRUITING", "last_update": "2024-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06484062", "title": "Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06536959", "title": "VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS", "status": "RECRUITING", "last_update": "2024-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06577441", "title": "Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06612944", "title": "Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification", "status": "RECRUITING", "last_update": "2024-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06778187", "title": "Oral-ATO for TP53-mutated Myeloid Malignancies", "status": "RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06923488", "title": "Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06928662", "title": "Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06972641", "title": "Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation", "status": "RECRUITING", "last_update": "2025-05-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07006025", "title": "A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)", "status": "RECRUITING", "last_update": "2026-01-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07044544", "title": "Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies", "status": "RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07238686", "title": "Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07283094", "title": "FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07500753", "title": "A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002832", "title": "Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2012-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002980", "title": "Decitabine in Treating Patients With Melanoma or Other Advanced Cancer", "status": "COMPLETED", "last_update": "2013-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003361", "title": "Decitabine in Treating Patients With Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00043134", "title": "Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2010-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00043381", "title": "Decitabine Versus Supportive Care in Adults With Advanced-stage MDS", "status": "COMPLETED", "last_update": "2024-08-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049582", "title": "Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00067808", "title": "Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2012-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00075010", "title": "Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2018-11-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00113321", "title": "Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure", "status": "TERMINATED", "last_update": "2012-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00114257", "title": "Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00260065", "title": "A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2013-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00282399", "title": "A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2015-10-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00321711", "title": "Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents", "status": "COMPLETED", "last_update": "2018-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00357708", "title": "Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases", "status": "COMPLETED", "last_update": "2013-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00382200", "title": "Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2024-05-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00414310", "title": "Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)", "status": "COMPLETED", "last_update": "2019-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00416598", "title": "Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00479232", "title": "Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)", "status": "COMPLETED", "last_update": "2015-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00619099", "title": "A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2013-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00621023", "title": "Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00671697", "title": "Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00691938", "title": "LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2016-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00740181", "title": "Decitabine, Cytarabine, GCSF for Refractory AML/MDS", "status": "TERMINATED", "last_update": "2022-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00744757", "title": "An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2013-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00760084", "title": "Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2011-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00778375", "title": "Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2016-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00796003", "title": "A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00828802", "title": "Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2013-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00882102", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)", "status": "COMPLETED", "last_update": "2013-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00903760", "title": "Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2018-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00906334", "title": "Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk", "status": "COMPLETED", "last_update": "2017-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00941109", "title": "Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2023-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968071", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00986804", "title": "Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant", "status": "COMPLETED", "last_update": "2016-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01011283", "title": "To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.", "status": "TERMINATED", "last_update": "2014-10-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130506", "title": "Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2017-08-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01133886", "title": "Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure", "status": "UNKNOWN", "last_update": "2010-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01165996", "title": "Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2019-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01211457", "title": "Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)", "status": "UNKNOWN", "last_update": "2019-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01241500", "title": "Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts", "status": "COMPLETED", "last_update": "2020-06-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01251627", "title": "Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia", "status": "COMPLETED", "last_update": "2018-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01277484", "title": "Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML", "status": "UNKNOWN", "last_update": "2015-11-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01333449", "title": "Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients", "status": "TERMINATED", "last_update": "2014-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01378416", "title": "Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2011-07-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01417767", "title": "Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS", "status": "UNKNOWN", "last_update": "2016-09-09", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01420926", "title": "Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2023-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01455506", "title": "PRO#0118: Decitabine Plus Mini Flu-Bu", "status": "COMPLETED", "last_update": "2014-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01546038", "title": "A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2020-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01567059", "title": "Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2017-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01593670", "title": "Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2019-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01607645", "title": "Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS", "status": "TERMINATED", "last_update": "2017-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01674985", "title": "Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2016-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01687400", "title": "Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2018-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01690507", "title": "Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML\uff09", "status": "COMPLETED", "last_update": "2016-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01707004", "title": "Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01720225", "title": "Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk", "status": "COMPLETED", "last_update": "2020-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01729845", "title": "Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2019-02-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01751867", "title": "An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2016-04-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01806116", "title": "Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation", "status": "UNKNOWN", "last_update": "2013-03-12", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01809392", "title": "Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2013-03-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01812252", "title": "Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant", "status": "COMPLETED", "last_update": "2024-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01834248", "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01846624", "title": "Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2018-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01893320", "title": "Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2022-02-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01893372", "title": "Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2020-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01928537", "title": "Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine", "status": "COMPLETED", "last_update": "2020-06-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01993641", "title": "Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA", "status": "COMPLETED", "last_update": "2017-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02010645", "title": "Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2020-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02013102", "title": "A Phase \u2163 Study of Decitabine in Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2013-12-17", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02029417", "title": "Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2016-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02084563", "title": "Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms", "status": "COMPLETED", "last_update": "2016-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02085408", "title": "Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-12-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02103478", "title": "Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2024-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02121418", "title": "Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm", "status": "COMPLETED", "last_update": "2018-04-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02129101", "title": "Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies", "status": "COMPLETED", "last_update": "2019-10-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02141477", "title": "Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2018-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02190695", "title": "Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS", "status": "COMPLETED", "last_update": "2021-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02197676", "title": "A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response", "status": "COMPLETED", "last_update": "2018-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02228525", "title": "Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2022-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264873", "title": "Phase I, Dose Escalation Study of Decitabine", "status": "COMPLETED", "last_update": "2018-10-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02269280", "title": "Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2025-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02272478", "title": "Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations", "status": "UNKNOWN", "last_update": "2020-01-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02281084", "title": "Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2024-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02469415", "title": "Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)", "status": "TERMINATED", "last_update": "2018-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02488408", "title": "A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS", "status": "COMPLETED", "last_update": "2024-12-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02562443", "title": "Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA", "status": "TERMINATED", "last_update": "2022-09-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02564536", "title": "Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)", "status": "WITHDRAWN", "last_update": "2017-05-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02649790", "title": "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications", "status": "COMPLETED", "last_update": "2025-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02744742", "title": "G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT", "status": "COMPLETED", "last_update": "2022-02-14", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02779569", "title": "A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)", "status": "UNKNOWN", "last_update": "2017-11-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02890329", "title": "Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02921061", "title": "Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS", "status": "COMPLETED", "last_update": "2020-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03045510", "title": "Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent", "status": "UNKNOWN", "last_update": "2017-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03066648", "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS", "status": "COMPLETED", "last_update": "2025-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03092674", "title": "Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2025-01-16", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03113071", "title": "Safety and Activity of Digoxin With Decitabine in Adult AML and MDS", "status": "TERMINATED", "last_update": "2021-03-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03146871", "title": "Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent", "status": "TERMINATED", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03164057", "title": "A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03184935", "title": "Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife\u00ae-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)", "status": "SUSPENDED", "last_update": "2026-04-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03306264", "title": "Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML", "status": "COMPLETED", "last_update": "2024-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03356080", "title": "DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess", "status": "UNKNOWN", "last_update": "2017-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03358719", "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03377725", "title": "Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)", "status": "WITHDRAWN", "last_update": "2023-08-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03404193", "title": "Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03502668", "title": "Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS", "status": "COMPLETED", "last_update": "2026-04-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03593915", "title": "A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS", "status": "TERMINATED", "last_update": "2023-11-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03613532", "title": "Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03813186", "title": "Effect of Food on Blood Levels of ASTX727", "status": "COMPLETED", "last_update": "2024-08-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03906695", "title": "Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03946670", "title": "A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).", "status": "TERMINATED", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03969446", "title": "Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory", "status": "SUSPENDED", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04013880", "title": "ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2020-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04055844", "title": "Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS", "status": "COMPLETED", "last_update": "2023-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04093570", "title": "A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04097470", "title": "Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04146038", "title": "Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease", "status": "COMPLETED", "last_update": "2023-05-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04155580", "title": "A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2024-08-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04623944", "title": "NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04655755", "title": "Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04713956", "title": "G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT", "status": "UNKNOWN", "last_update": "2021-01-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04878432", "title": "STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS", "status": "TERMINATED", "last_update": "2025-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04891757", "title": "FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04980404", "title": "Inqovi Maintenance Therapy in Myeloid Neoplasms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04985656", "title": "A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes", "status": "WITHDRAWN", "last_update": "2021-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04999943", "title": "Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2021-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05038592", "title": "Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05148234", "title": "BMS-986253 in Myelodysplastic Syndromes", "status": "TERMINATED", "last_update": "2025-09-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05201066", "title": "Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05426798", "title": "Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes", "status": "UNKNOWN", "last_update": "2022-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05453552", "title": "G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT", "status": "UNKNOWN", "last_update": "2023-03-21", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05455294", "title": "Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05456269", "title": "A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS", "status": "WITHDRAWN", "last_update": "2023-10-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564650", "title": "Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05600894", "title": "Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05766514", "title": "Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction", "status": "WITHDRAWN", "last_update": "2025-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05796570", "title": "A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05829226", "title": "A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2026-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05835011", "title": "A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)", "status": "TERMINATED", "last_update": "2024-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05883956", "title": "A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05918055", "title": "Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes", "status": "TERMINATED", "last_update": "2025-12-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06091267", "title": "PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06284460", "title": "Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms", "status": "WITHDRAWN", "last_update": "2026-02-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06337331", "title": "Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant", "status": "WITHDRAWN", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06572631", "title": "Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor", "status": "WITHDRAWN", "last_update": "2025-05-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153497", "title": "Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07617363", "title": "ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07710534", "title": "Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ENASIDENIB": { "n": 12, "n_observational": 0, "n_active": 8, "n_withdrawn": 0, "trials": [ { "nct": "NCT03383575", "title": "Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03683433", "title": "Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06577441", "title": "Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01915498", "title": "Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation", "status": "COMPLETED", "last_update": "2024-10-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02632708", "title": "Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03744390", "title": "IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03839771", "title": "A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04522895", "title": "IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05282459", "title": "Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation", "status": "COMPLETED", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "EPRENETAPOPT": { "n": 4, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03072043", "title": "Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms", "status": "COMPLETED", "last_update": "2022-01-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03588078", "title": "Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine", "status": "UNKNOWN", "last_update": "2020-01-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03745716", "title": "APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2025-03-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03931291", "title": "APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NAVITOCLAX": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05455294", "title": "Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564650", "title": "Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "NAVTEMADLIN": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04190550", "title": "Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "OBATOCLAX": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00413114", "title": "Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2013-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00438178", "title": "Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies", "status": "COMPLETED", "last_update": "2014-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "SIREMADLIN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03940352", "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2025-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "VENETOCLAX": { "n": 110, "n_observational": 2, "n_active": 70, "n_withdrawn": 3, "trials": [ { "nct": "NCT02115295", "title": "Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03113643", "title": "SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03214562", "title": "Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03471260", "title": "Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03661307", "title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03850574", "title": "Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03874052", "title": "Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04068597", "title": "Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140487", "title": "Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04256317", "title": "A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04581512", "title": "Study to Evaluate the Safety and Tolerability of EP0042", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04628026", "title": "Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04708054", "title": "Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04988555", "title": "A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)", "status": "RECRUITING", "last_update": "2026-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010122", "title": "ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05025098", "title": "Precision Therapy Versus Standard Therapy in AML and MDS in Elderly", "status": "RECRUITING", "last_update": "2021-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05184842", "title": "Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML", "status": "RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05211570", "title": "AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05292664", "title": "Venetoclax Basket Trial for High Risk Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05342584", "title": "Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS", "status": "RECRUITING", "last_update": "2026-01-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05365035", "title": "A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts", "status": "RECRUITING", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554406", "title": "Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05584761", "title": "Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML", "status": "RECRUITING", "last_update": "2022-10-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05807932", "title": "Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML", "status": "RECRUITING", "last_update": "2024-05-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05986240", "title": "Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML", "status": "RECRUITING", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06046313", "title": "Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS", "status": "RECRUITING", "last_update": "2024-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06329999", "title": "A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML", "status": "RECRUITING", "last_update": "2024-03-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06357182", "title": "Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06372717", "title": "A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06399640", "title": "Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06419634", "title": "Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06471946", "title": "VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS", "status": "RECRUITING", "last_update": "2024-10-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06501196", "title": "A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06536959", "title": "VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS", "status": "RECRUITING", "last_update": "2024-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06548230", "title": "A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-03-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06778187", "title": "Oral-ATO for TP53-mutated Myeloid Malignancies", "status": "RECRUITING", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06918834", "title": "Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients", "status": "RECRUITING", "last_update": "2025-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06972641", "title": "Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation", "status": "RECRUITING", "last_update": "2025-05-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07044544", "title": "Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies", "status": "RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07047183", "title": "Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes", "status": "RECRUITING", "last_update": "2025-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07183878", "title": "Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07228273", "title": "Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07238686", "title": "Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07270978", "title": "Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07283094", "title": "FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01211457", "title": "Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)", "status": "UNKNOWN", "last_update": "2019-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02250937", "title": "Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02392572", "title": "ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02397720", "title": "Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02942290", "title": "A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Na\u00efve Higher-Risk Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02966782", "title": "A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)", "status": "COMPLETED", "last_update": "2023-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03176277", "title": "A Study of ONO-7475 in Patients With Acute Leukemias", "status": "TERMINATED", "last_update": "2024-07-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03404193", "title": "Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03613532", "title": "Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03862157", "title": "Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940352", "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2025-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03969446", "title": "Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory", "status": "SUSPENDED", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04017546", "title": "CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04146038", "title": "Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease", "status": "COMPLETED", "last_update": "2023-05-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04160052", "title": "Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2026-02-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04227847", "title": "A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278768", "title": "Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "status": "SUSPENDED", "last_update": "2026-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04284787", "title": "BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04401748", "title": "Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "status": "TERMINATED", "last_update": "2025-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04487106", "title": "Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2025-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04550442", "title": "Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia", "status": "TERMINATED", "last_update": "2026-06-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04609826", "title": "A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2025-10-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04655755", "title": "Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04752163", "title": "DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia", "status": "TERMINATED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04809181", "title": "Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04812548", "title": "A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants", "status": "TERMINATED", "last_update": "2025-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04874194", "title": "Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1", "status": "TERMINATED", "last_update": "2025-11-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04912063", "title": "Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2024-02-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04937166", "title": "A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies", "status": "TERMINATED", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05005299", "title": "Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation", "status": "UNKNOWN", "last_update": "2023-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05107856", "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies", "status": "TERMINATED", "last_update": "2024-01-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05168202", "title": "A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes", "status": "TERMINATED", "last_update": "2025-09-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05201066", "title": "Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05209152", "title": "AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia", "status": "TERMINATED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05275439", "title": "Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML", "status": "TERMINATED", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05367401", "title": "A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants", "status": "WITHDRAWN", "last_update": "2024-04-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05379166", "title": "Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05428969", "title": "A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05448599", "title": "A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS", "status": "UNKNOWN", "last_update": "2023-03-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05455294", "title": "Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05554419", "title": "Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564650", "title": "Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05600894", "title": "Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05665530", "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies", "status": "COMPLETED", "last_update": "2026-01-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05673057", "title": "Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05766514", "title": "Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction", "status": "WITHDRAWN", "last_update": "2025-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05782127", "title": "Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05823714", "title": "Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT", "status": "UNKNOWN", "last_update": "2023-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05829226", "title": "A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2026-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06050941", "title": "Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06109064", "title": "Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS", "status": "UNKNOWN", "last_update": "2023-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06337331", "title": "Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant", "status": "WITHDRAWN", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06454409", "title": "Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "SUSPENDED", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563804", "title": "A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML", "status": "TERMINATED", "last_update": "2026-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06598384", "title": "VA as Maintenance Therapy Post Allo-HSCT in MDS and AML", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06765928", "title": "Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153497", "title": "Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07214064", "title": "Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation", "status": "NOT_YET_RECRUITING", "last_update": "2025-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07319793", "title": "Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07710534", "title": "Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07735117", "title": "Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "VORASIDENIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] } } } }